ClinicalTrials.gg

Program

ruzasvir

Also written as “Ruzasvir”, “Bemnifosbuvir/Ruzasvir (BEM/RZR)” and “Ruzasvir 60 mg”.

Its studies are mostly in Hepatitis C, Chronic · Hepatitis C, led by 2 companies.

Furthest: phase 2, since Jan 6, 20157 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck50 open or runningphase 2since Jan 6, 2015Feb 27, 2014none ahead
Atea Pharmaceuticals20 open or runningphase 2since Jun 6, 2023Jun 6, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 27, 2014First study: phase 1 study in Hepatitis CNew to MerckMerck · NCT02076100 · 22 enrolled
  2. Jan 6, 2015Phase 2 study in Hepatitis CMerck · NCT02332707 · 443 enrolled
  3. Jan 25, 2016Phase 1 study in Hepatitis C, ChronicMerck · NCT02666352 · 24 enrolled
  4. Apr 29, 2016Phase 2 study in Hepatitis C, ChronicMerck · NCT02759315 · 160 enrolled
  5. Nov 2, 2016Phase 2 study in Hepatitis CMerck · NCT02956629 · 282 enrolled
  6. Jun 6, 2023Atea Pharmaceuticals's first study: phase 2 study in Hepatitis C, ChronicNew to Atea PharmaceuticalsAtea Pharmaceuticals · NCT05904470 · 275 enrolled · United States, Brazil, Canada and more
  7. Nov 19, 2025Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT07272889 · 24 enrolled · Canada

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Nonstructural protein 5A inhibitor”ChEMBL 37, by rule

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07272889Healthy Volunteer Study · Canada1CompletedAtea PharmaceuticalsFeb 17, 202624
NCT05904470Hepatitis C, Chronic · United States, Brazil, Canada and more2CompletedAtea PharmaceuticalsDec 9, 2024275
NCT02956629Hepatitis C2TerminatedMerckDec 22, 2017282
NCT02759315Hepatitis C, Chronic2TerminatedMerckJul 27, 2017160
NCT02666352Hepatitis C, Chronic1CompletedMerckJan 16, 201724
NCT02332707Hepatitis C2CompletedMerckSep 16, 2016443
NCT02076100Hepatitis C1CompletedMerckNov 15, 201522

How it is read

Names in the registry

  • “Ruzasvir”, 5 entries
  • “Bemnifosbuvir/Ruzasvir (BEM/RZR)”, 1 entry
  • “Ruzasvir 60 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.